Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After Recent Share Price Weakness

Simply Wall St.04-17 20:05

CSPC Pharmaceutical Group (SEHK:1093) has drawn investor attention after recent share price moves, with the stock showing a 4.2% decline over the past day and an 8.9% decline over the past 3 months. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628020707?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-04-17 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628020707","market":"hk","top_or_hot":-1,"title":"Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>CSPC Pharmaceutical Group (SEHK:1093) has drawn investor attention after recent share price moves, with the stock showing a 4.2% decline over the past day and an 8.9% decline over the past 3 months. ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/assessing-cspc-pharmaceutical-group-sehk1093-valuation-after-3\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-17 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/assessing-cspc-pharmaceutical-group-sehk1093-valuation-after-3><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CSPC Pharmaceutical Group (SEHK:1093) has drawn investor attention after recent share price moves, with the stock showing a 4.2% decline over the past day and an 8.9% decline over the past 3 months. ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/assessing-cspc-pharmaceutical-group-sehk1093-valuation-after-3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1226288253.USD","symbol_name":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/assessing-cspc-pharmaceutical-group-sehk1093-valuation-after-3","article_id":"2628020707","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/assessing-cspc-pharmaceutical-group-sehk1093-valuation-after-3","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628020707","pubTimestamp":1776427546,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CSPC Pharmaceutical Group (SEHK:1093) has drawn investor attention after recent share price moves, with the stock showing a 4.2% decline over the past day and an 8.9% decline over the past 3 months.\nSee our latest analysis for CSPC Pharmaceutical Group.\nThe recent 4.2% one-day share price decline sits within a softer near-term pattern, with a 90-day share price return of negative 8.9%, even as the 1-year total shareholder return of 65.7% and 3-year total shareholder return of 27.2% point to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1191":"制药","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","01093":"石药集团","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1515":"抗疫概念","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","BK1521":"挪威政府全球养老基金持仓","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC"},"translate_title":"在近期股价疲软后评估石药集团（SEHK：1093）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"01093":0.9},"content_text":"CSPC Pharmaceutical Group (SEHK:1093) has drawn investor attention after recent share price moves, with the stock showing a 4.2% decline over the past day and an 8.9% decline over the past 3 months. See our latest analysis for CSPC Pharmaceutical Group. The recent 4.2% one-day share price decline sits within a softer near-term pattern, with a 90-day share price return of negative 8.9%, even as the 1-year total shareholder return of 65.7% and 3-year total shareholder return of 27.2% point to much stronger longer-term gains and shifting expectations about growth and risk. If CSPC Pharmaceutical Group has caught your eye, this is also a good moment to see what else the market is pricing into healthcare focused AI names using our screener for 126 healthcare AI stocks With CSPC Pharmaceutical Group trading at HK$8.96 and various fair value and analyst measures implying higher levels, the key question for you is whether this suggests an undervalued entry point or if the market already reflects expectations for future growth in the share price. AdvertisementPrice to Earnings of 23x: Is it justified? CSPC Pharmaceutical Group is trading on a P/E of 23x at a last close of HK$8.96, which sits between its peer group and the wider industry. The P/E ratio compares the current share price with earnings per share, so it reflects how much investors are paying for each unit of current earnings. For a company in pharmaceuticals, where investors often focus on the earnings profile from established products and the future pipeline, this can be a useful shorthand for how the market is weighing the earnings outlook against current results. On one side, the stock is described as good value compared to the peer average P/E of 26.5x and also below an estimated fair P/E of 28.1x. This points to some valuation headroom that the market could move toward if sentiment or earnings expectations shift. On the other side, it is labelled expensive versus the Hong Kong Pharmaceuticals industry average P/E of 15.5x, which suggests investors are currently paying a premium over the broader group for CSPC Pharmaceutical Group's earnings. Explore the SWS fair ratio for CSPC Pharmaceutical Group Result: Price-to-earnings of 23x (ABOUT RIGHT) However, there are still clear risks, including tighter pricing pressure in Mainland China and execution challenges across CSPC Pharmaceutical Group's broad drug portfolio and international markets. Find out about the key risks to this CSPC Pharmaceutical Group narrative. Another view using future cash flows While a 23x P/E suggests CSPC Pharmaceutical Group sits around fair value on earnings today, the SWS DCF model presents a different view, with a fair value estimate of HK$17.76 per share versus the current HK$8.96. That gap raises a simple question: is the market underestimating future cash flows? For a closer look at how those long term cash flow assumptions compare, have a look at the SWS DCF workup, Look into how the SWS DCF model arrives at its fair value. 1093 Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CSPC Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 228 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Overall, the picture here combines optimism with clear concerns. It makes sense to review the numbers yourself, weigh the trade offs, and then check the 2 key rewards and 1 important warning sign. Looking for more investment ideas? If CSPC Pharmaceutical Group interests you, do not stop here. Broaden your watchlist with stocks that match your style so you are not missing potential opportunities.  Target quality at a reasonable price by reviewing companies in the 228 high quality undervalued stocks that pair strong fundamentals with what may be appealing valuations. Build a steadier income stream by checking out the 478 dividend fortresses and focus on businesses offering higher yields with an emphasis on stability. Prioritise resilience by scanning the 296 resilient stocks with low risk scores so you can focus on companies that score well on financial strength and risk measures.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628020707","isCrawlerRequest":true}